FindMyKOL

Ilana Schlam Camhi, MD, MPH

Enriched profile

Assistant Professor of Medicine, Harvard Medical School · Dana-Farber Cancer Institute

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyHematology / OncologyFocusBreast Cancer Treatment Studies+4
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Ilana Schlam Camhi is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. OpenAlex indexes 107 publications with 1,454 citations (h-index 19); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 9 Nov 2026

Overview

Updated 9 Nov 2026

Ilana Schlam Camhi is Assistant Professor of Medicine, Harvard Medical School at Dana-Farber Cancer Institute. The public record shows 107 publications with 1,454 citations (h-index 19), centered on Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 5 companies.

  • Most recent indexed publication: 2026 · Therapeutic advances in medical oncology
  • Top research focus: Breast Cancer Treatment Studies
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 5 companies

Generated from the cited public record · current as of 9 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Breast Cancer1 trialColorectal CancerDyslipidemia / Lipid DisordersGastroesophageal CancerNeuro-Oncology / GliomaLeukemia (AML/ALL/CML/CLL)LymphomaMultiple MyelomaLung Cancer (NSCLC/SCLC)Prostate Cancer

Research focus

OpenAlex concept fingerprint
Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchAdvanced Breast Cancer TherapiesCancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigation

Drugs & molecules

across trials, industry payments and publications
Kisqaligeneric · RibociclibClinical trials—Industry payments4Publications—Enhertugeneric · TrastuzumabClinical trials—Industry payments2Publications—Epkinlygeneric · EpcoritamabClinical trials—Industry payments1Publications—Imbruvicageneric · IbrutinibClinical trials—Industry payments1Publications—Lynparzageneric · OlaparibClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Novartis Pharmaceuticals CorporationClinical trials—Industry payments4Daiichi Sankyo Inc.Clinical trials—Industry payments2Pharmacyclics LLC, An AbbVie CompanyClinical trials—Industry payments2AstraZeneca Pharmaceuticals LPClinical trials—Industry payments1AstraZeneca UK LimitedClinical trials—Industry payments1Yale UniversityClinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
107publications

Publications indexed by OpenAlex, matched via ORCID. 15 in PubMed. Counts exclude supporting files.

1,454citations

Citations across these publications.

19h-index

H-index from these publications. i10-index 30.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
5companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →

Clinical trials

Updated 9 Nov 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 9 Nov 2026

5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 6 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 9 Nov 2026

25 congress contributions (2018–2026) across AACR, AHA, ASCO, ASH, ESMO per OpenAlex. The most recent:

All 25 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 9 Nov 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 15 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
All 107 cited works: search, sort and filter.Explore →

Network

Updated 9 Nov 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Sara M. Tolaney39Paolo Tarantino19Sandra M. Swain15Filipa C. Lynce14NU Lin9Ana Christina Garrido-Castro9Christopher Gallagher9Sarah LeNoir Sammons8Ami Chitalia8Shruti Rakesh Tiwari7Charles J. Glueck7Giuseppe Curigliano6Claudine J. Isaacs6Jenica N. Upshaw6Candace Bavette Mainor5Brent T. Harris5Elizabeth Ann Mittendorf5Ana Barac5Dario Trapani5Joshua Dower5Heather Anne Parsons5Jordan B. Strom4Rafaël Fonseca4Xue Geng4Kelly A. Hirko4Murat Akdere4Matan Rothschild4Margaret Elena Gatti-Mays4Raquel Nunes4Komal L. Jhaveri4Fei Song4Sarah Min4Stefania Morganti4Sarah Sewaralthahab4Nabihah Tayob4Daniela Shveid Gerson4Esther Pasternak4Jingyi Gong4Kristi D. Graves4Asma Ali Dilawari4

Background & recognition

Updated 9 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Associate Director

    Early Breast Cancer Program (LEAP), Dana-Farber Cancer Institute

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lbbc.org ↗

Awards & honors

honors on the public record

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.